DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Atacand (Candesartan Cilexetil) - Summary

 
 



ATACAND SUMMARY

ATACAND (candesartan cilexetil), a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.

ATACAND is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.


See all Atacand indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Atacand (Candesartan Cilexetil)

Research suggests team-based care is most effective way to control hypertension
Source: Hypertension News From Medical News Today [2014.10.24]
Patients diagnosed with high blood pressure are given better control of their condition from a physician-pharmacist collaborative intervention than physician management alone, according to new...

Exalenz Bioscience launches pivotal study of world's first breath-based test to diagnose clinically significant portal hypertension
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.10.23]
Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced the start of a pivotal...

Binge drinking in young men linked with increased risk of hypertension
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2014.10.21]
Binge drinking in early adulthood is associated with an increased likelihood of high blood pressure in males, while low to moderate alcohol use in early adulthood is associated with a decreased...

Uncontrolled hypertension highest among patients with moderate-to-severe psoriasis
Source: Hypertension News From Medical News Today [2014.10.20]
Patients with moderate and severe psoriasis have the greatest likelihood of uncontrolled hypertension compared to patients without psoriasis.

UF researchers use plants to study new ways of delivering drugs for pulmonary hypertension
Source: Endocrinology News From Medical News Today [2014.10.17]
UF researchers are using the leaves of plants to study new ways to deliver drugs that treat pulmonary hypertension, a disease with few treatment options, according to a study published online in...

more news >>

Published Studies Related to Atacand (Candesartan Cilexetil)

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. [2012]
Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. This 16-week, multicenter, randomized, double-blind study compared the efficacy and safety of azilsartan (20-40 mg once daily by forced titration) and its ability to provide 24-h blood pressure (BP) control, with that of candesartan cilexetil (candesartan; 8-12 mg once daily by forced titration) in 622 Japanese patients with grade I-II essential hypertension.

Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. [2011]
hypertension and type 2 diabetes mellitus... CONCLUSION: CC/PIO combination therapy improved BP/glycemic control and was well

Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. [2010.05]
CONCLUSION: Candesartan cilexetil dose-dependently decreases blood pressure and albuminuria in hypertensive infants and is generally well tolerated.

Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. [2010.03]
BACKGROUND: Hypertension is a risk factor for the two leading causes of death in renal transplant recipients: cardiovascular disease (CVD) and graft failure. Despite this, the optimum medication for post-transplant hypertension is unclear... CONCLUSIONS: SECRET provides insights into the design and conduct of studies in this area and evidence for the utility of candesartan, which showed good safety and tolerability, improved BP control and decreased proteinuria in renal transplant recipients.

Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. [2009.12]
OBJECTIVE: The aim of this study was to elucidate the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activating angiotensin receptor blocker (ARB) telmisartan and the non-PPAR-gamma activating ARB valsartan and candesartan on mycophenolic acid (MPA) pharmacokinetics in renal transplant recipients... CONCLUSIONS: The degree of drug interaction between MPA and telmisartan was significantly greater than that between MPA and valsartan or candesartan. Uridine diphosphate-glucuronosyltransferase (UGT) 1A9 has been identified as a PPAR-gamma target gene. UGT induction by telmisartan might stimulate MPA glucuronidation. A combination of telmisartan and mycophenolate mofetil might require periodic monitoring of MPA.

more studies >>

Clinical Trials Related to Atacand (Candesartan Cilexetil)

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age [Active, not recruiting]
This is a dose ranging study of candesartan cilexetil in hypertensive pediatric subjects ages 1 to less than 6 years of age. It employs a double blind, randomized, dose ranging design intended for conduct as a multicenter trial. There are 3 study 'periods': a 1-week placebo run-in, a 4-week double blind treatment, and a 52-week open-label, long-term treatment period. Subjects undergo a screening evaluation, then a 1-week single-blind, placebo run-in, after which eligible subjects are allocated to receive 1 of 3 dose levels of candesartan cilexetil (0. 05 mg/kg, or 0. 20 mg /kg or 0. 40 mg /kg), liquid formulation, in a 1: 1:1 ratio for 4-weeks. At the end of randomized dose allocation (Day 28), blood pressure assessment will be performed and subjects may begin the 52-week, open-label treatment period of the study.

Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide [Completed]
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12. 5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i. e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.

Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH [Completed]
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12. 5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i. e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..

DIabetic Retinopathy Candesartan Trials. [Active, not recruiting]
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate of change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 2 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg [Completed]
In this study it is intended to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the combination of candesartan 32 mg and HCT 12. 5 mg to that of candesartan 32 mg alone in patients whose blood pressure is not well controlled on candesartan 32 mg monotherapy. The Primary Objectives are to compare sitting BP lowering effect of candesartan/HCT 32/25 mg and candesartan/HCT 32/12. 5 mg with that of candesartan 32 mg, respectively.

more trials >>

Reports of Suspected Atacand (Candesartan Cilexetil) Side Effects

Hypertension (126)Drug Ineffective (109)Malaise (101)Blood Pressure Increased (94)Drug Dose Omission (81)Dizziness (72)Cerebrovascular Accident (61)Headache (46)Diabetes Mellitus (40)Fall (40)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 4 ratings/reviews, Atacand has an overall score of 9. The effectiveness score is 8.50 and the side effect score is 8.50. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Atacand review by 50 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   16mg taken once a day for the period of 2 years
Other conditions:   none
Other drugs taken:   no other drugs but on HRT
  
Reported Results
Benefits:   lowered blood pressure
Side effects:   I did experience some bowel changes although the doctor did not seem to think that this would be the result of the drug. I do, however. I experienced constipation.
Comments:   One 16 mg tablet to be taken daily. I had been given other blood pressure medication previously which I did not respond as well to so It took a few tries to get it right. I would like to be able to stop taking the medication and am trying to lose weight and lead a healthier lifestyle but all the literature seems to suggest that I may always need to take the medication.

 

Atacand review by 73 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   8 mg taken once per day for the period of several years
Other conditions:   none
Other drugs taken:   vitamins, folic acid, vit-D3
  
Reported Results
Benefits:   The Atacand worked well for me IF taken consistently without skipping days. I was able to bring my blood pressure to at least 120/80 and at times a bit lower. Note that consistency of medication is a key. Should the 8mg tablet taken once per day not prove as effective as desired, my physician advised that I could take an additional tablet or two per day without problem.
Side effects:   Did not notice any undesirable side effects. The only thing that could be mentioned is that if one embarks on a significant exercise routine such as elleptical stairstep machine for 30+ minutes/day and keeps up the exercise for weeks on end while at the same time taking the Atacand, one may end up with a [not undesirable] blood pressure in the 112/65 range.
Comments:   The Atacand worked well IF taken routinely without skipping days. It takes a while for the regulation to start, ie, you can't begin from scratch taking the Atacand the first morning and expect proper blood pressure regulation that afternoon. Doesn't work that quickly. There is a tendency, after taking the medication consistently and seeing your pressure get well under control, to think that maybe you can stop or at least taper off of the Atacand. One may try this but will find that the best regimen is consistency. It did work well for me and keeps me under 120/80.

 

Atacand review by 73 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   8 mg taken once per day for the period of several years
Other conditions:   none
Other drugs taken:   vitamins, folic acid, vit-D3
  
Reported Results
Benefits:   The Atacand worked well for me IF taken consistently without skipping days. I was able to bring my blood pressure to at least 120/80 and at times a bit lower. Note that consistency of medication is a key. Should the 8mg tablet taken once per day not prove as effective as desired, my physician advised that I could take an additional tablet or two per day without problem.
Side effects:   Did not notice any undesirable side effects. The only thing that could be mentioned is that if one embarks on a significant exercise routine such as elleptical stairstep machine for 30+ minutes/day and keeps up the exercise for weeks on end while at the same time taking the Atacand, one may end up with a [not undesirable] blood pressure in the 112/65 range.
Comments:   The Atacand worked well IF taken routinely without skipping days. It takes a while for the regulation to start, ie, you can't begin from scratch taking the Atacand the first morning and expect proper blood pressure regulation that afternoon. Doesn't work that quickly. There is a tendency, after taking the medication consistently and seeing your pressure get well under control, to think that maybe you can stop or at least taper off of the Atacand. One may try this but will find that the best regimen is consistency. It did work well for me and keeps me under 120/80.

See all Atacand reviews / ratings >>

Page last updated: 2014-10-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014